Methadone, Pierre Robin sequence and other congenital anomalies: case-control study.
Adult
Case-Control Studies
Cleft Palate
/ epidemiology
Comorbidity
Europe
Female
Gestational Age
Humans
Infant, Newborn
Male
Methadone
/ administration & dosage
Opioid-Related Disorders
/ drug therapy
Pierre Robin Syndrome
/ epidemiology
Pregnancy
Prenatal Exposure Delayed Effects
/ epidemiology
Risk Assessment
Pierre Robin sequence
cleft palate
methadone
opioid use disorder
Journal
Archives of disease in childhood. Fetal and neonatal edition
ISSN: 1468-2052
Titre abrégé: Arch Dis Child Fetal Neonatal Ed
Pays: England
ID NLM: 9501297
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
06
01
2019
revised:
11
05
2019
accepted:
14
05
2019
pubmed:
24
6
2019
medline:
10
3
2020
entrez:
24
6
2019
Statut:
ppublish
Résumé
Methadone is a vital treatment for women with opioid use disorder in pregnancy. Previous reports suggested an association between methadone exposure and Pierre Robin sequence (PRS), a rare craniofacial anomaly. We assessed the association between gestational methadone exposure and PRS. This case-malformed control study used European Surveillance of Congenital Anomalies population-based registries in Ireland, the Netherlands, Italy, Switzerland, Croatia, Malta, Portugal, Germany, Wales, Norway and Spain, 1995-2011. Cases included PRS based on International Classification of Disease (ICD), Ninth Edition-British Paediatric Association (BPA) code 75 603 or ICD, Tenth Edition-BPA code Q8708. Malformed controls were all non-PRS anomalies, excluding genetic conditions, among live births, fetal deaths from 20 weeks' gestation and terminations of pregnancy for fetal anomalies. An exploratory analysis assessed the association between methadone exposure and other congenital anomalies (CAs) excluding PRS. Methadone exposure was ascertained from medical records and maternal interview. Among 87 979 CA registrations, there were 127 methadone-exposed pregnancies and 336 PRS cases. There was an association between methadone exposure and PRS (OR adjusted for registry 12.3, 95% CI 5.7 to 26.8). In absolute terms, this association reflects a risk increase from approximately 1-12 cases per 10 000 births. A raised OR was found for cleft palate (adjusted OR 5.0, 95% CI 2.7 to 9.2). These findings suggest that gestational methadone exposure is associated with PRS. The association may be explained by unmeasured confounding factors. The small increased risk of PRS in itself does not alter the risk-benefit balance for gestational methadone use. The association with cleft palate, a more common CA, should be assessed with independent data.
Identifiants
pubmed: 31229957
pii: archdischild-2019-316804
doi: 10.1136/archdischild-2019-316804
doi:
Substances chimiques
Methadone
UC6VBE7V1Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
151-157Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.